肺癌新辅助免疫治疗研究进展  

Advances in neoadjuvant immunotherapy for lung cancer

作　　者：蔡刚祥[1] 李境 许斌[2] Cai Gangxiang;Li Jing;Xu Bin(Department of Oncology,People’s Hospital of Jiayu County of Xianning City of Hubei Province,Jiayu 437200,China;Cancer Center,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]湖北省咸宁市嘉鱼县人民医院肿瘤科,嘉鱼437200 [2]武汉大学人民医院肿瘤中心,武汉430060

出　　处：《国际肿瘤学杂志》2022年第6期366-370,共5页Journal of International Oncology

摘　　要：新辅助免疫治疗可降低可切除肺癌患者术后复发或远处转移风险,延长患者生存期,其疗效优于新辅助化疗。小样本研究表明新辅助免疫治疗联合化疗方案相比于新辅助免疫单药方案的主要病理缓解率更高,但其治疗相关不良事件发生率也更高、治疗周期更长,可导致手术的延迟、增加术中并发症的风险。新辅助免疫治疗的方案选择、手术时机、疗效评估等问题仍未有定论,多项新辅助免疫治疗单药及联合方案的Ⅲ期临床研究正在进行中,期待通过长期随访数据进一步验证新辅助免疫治疗的疗效。Neoadjuvant immunotherapy can reduce the risk of postoperative recurrence or distant metastasis in patients with resectable lung cancer,prolong the survival of patients,and has better efficacy compared to neoadjuvant chemotherapy.Existing clinical trials with a small sample size indicate that neoadjuvant immunotherapy combined with chemotherapy has a higher rate of major pathologic response compared to single-agent immunotherapy,but it is also accompanied by a higher incidence of treatment-related adverse events and a longer treatment cycle,which may lead to delayed surgery or increased risk of intraoperative complications.The selection of therapeutic regimens,surgical timing,efficacy evaluation,and other issues have not been determined.Several phaseⅢclinical studies of a single drug and combined regimen of neoadjuvant immunotherapy are ongoing,and the efficacy of neoadjuvant immunotherapy is expected to be further verified through follow-up data.

关 键 词：肺肿瘤 免疫疗法 治疗结果 新辅助疗法 

分 类 号：R734.2[医药卫生—肿瘤]